

Oncology Test Request

Client Information (requir	red)		Patient Informa	tion (required)			
Client Name			Patient ID (Medical Record No.)				
Client Account No.			Patient Name (Last, F	irst Middle)			
Client Phone	Client Or	der No.	Sex ☐ Male ☐ Fema			Birth Date (mm-dd-yyyy)	
Street Address		Collection Date (mm	Collection Date (mm-dd-yyyy)		Time ☐ am ☐ pm		
City	State	ZIP Code	Specimens Provided				
Submitting Healthcare Professional Information (required)			☐ Blood ☐ Bone marrow ☐ Fixed cells	☐ Paraffin b No. sent: Indicate s		☐ Tissue No. sent:	
Submitting/Referring Healthca		Name (Last, First)	☐ Cultured cells ☐ DNA			☐ Fixed formalin☐ Wet tissue	
Fill in only if Call Back is require			Lymph node			☐ Other fixative	
Phone (with area code)	Fax* (with	h area code)	☐ Spleen		Тур		
National Provider Identification (NPI)				☐ Slides No. sent:		☐ Other Anatomic site:	
*Fax number given must be from a fax n HIPAA regulation.	nachine that compli	es with applicable					
Pathologist Information	(required)		CBC Results	DDO		WDO	
Submitting/Referring Patholog				RBC:			
Submitting/Referring Fatholog	ist ivaille (Last, Fil	St.)		MCV:		PLT:	
Phone (with area code) Fax* (with area code)		 If ordering HER2 testing: Was specimen fixed in 10% neutral buffered formalin within 1 hour of surgical collection time? ☐ Yes ☐ No 					
National Provider Identification (NPI)			-	fixed in 10% neu		red formalin for 6 to	
*Fax number given must be from a fax n HIPAA regulation.			Pathologist/Cli	nical Diagnos	s is (requir	red)	
New York State Patients: Informed C	onsent for Genetic	Testing				ected diagnosis, and reason	
"I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office."		for referral.					
Signature							
Note: It is the client's responsibility to n	naintain documenta	tion of the order.					
MCL Internal Use Only			ICD-10 Diagnosis Co	ode			
Ship specimens to: Mayo Clinic Laboratories			Billing Information • An itemized invoice will				
3050 Superior Drive NW			Payment terms are net 30 days.				

T720

Rochester, MN 55905

Customer Service: 800-533-1710

Call the Business Office with billing-related questions:

800-447-6424 (US and Canada) 507-266-5490 (outside the US)

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

FEATURED ONCOLOGY TESTING

PD-L1 Immunohistochemical stains					
□ 22C3	Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual				
□ 288PD	Programmed Death-Ligand 1 (PD-L1) (28-8), Semi-Quantitative Immunohistochemistry, Manual				
☐ SP142	Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual				
☐ SP263	Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual				
Microsatellite Instability (MSI)/Mismatch Repair					
☐ TMSI	Microsatellite Instability, Tumor				
□ IHC	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor				
Pan-Cancer Biomarkers					
□ NTRK	NTRK Gene Fusion Panel, Tumor				
□ NTRKM	NTRK Genes Mutation Analysis, Next-Generation Sequencing, Tumor				
☐ BRAFD	BRAF V600E/V600K Somatic Mutation				

Next-Gener	ration Sequencing (NGS) Panels
□ мсврр	MayoComplete Bladder Prostate Panel
☐ MCCRC	MayoComplete Colorectal Cancer Panel, Next-Generation Sequencing, Tumor
☐ MCSRC	MayoComplete Comprehensive Sarcoma Panel, Next-Generation Sequencing, Tumor
□ МСЕСР	MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumor
□ MCGST	MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor
☐ MCGYN	MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor
□ мскср	MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor
☐ MCLNG	MayoComplete Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor
☐ MCMLN	MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor
☐ MCSTP	MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor

□ NONCP	Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor		
☐ MCOCP	MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor		
☐ MCFRC	MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor		
□ SARCP	Sarcoma Targeted Gene Fusion/ Rearrangement Panel, Next-Generation Sequencing, Tumor		
Chromoson	nal Microarray		
☐ CMAPT	Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded		
Cell-Free D	NA (cfDNA) Testing		
☐ BRAFB	Cell-Free DNA BRAF V600, Blood		
□ т790М	Cell-Free DNA EGFR T790M Mutation Analysis, Blood		
☐ KRASD	Cell-Free DNA KRAS 12, 13, 61, 146, Blood		
☐ MCLBP	MayoComplete Liquid Biopsy Panel, Next- Generation Sequencing, Cell-Free DNA		

PATHOLOGY

☐ PATHC Pathology Consultation
Appropriate stains and ancillary testing
may be performed in order to render an
accurate diagnosis

Analysis, Tumor

PATHOLOGY: TARGETED TUMOR TESTING

Bone and Soft Tissue

☐ EWSF

☐ FOXOF Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue ☐ TFE3F Alveolar Soft Part Sarcoma (ASPS)/ Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue ☐ MASF Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue ☐ CTNBT B-Catenin Mutations Analysis, Next-Generation Sequencing, Tumor ☐ DICET DICER1 Mutation Analysis, Next-Generation Sequencing, Tumor ☐ ETV6F ETV6 (12p13.2) Rearrangement, FISH, Tissue ☐ ESTUF Endometrial Stromal Tumors (EST), 7p15

(JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE)

Ewing Sarcoma (EWS), 22q12 (EWSR1) Rearrangement, FISH, Tissue

Rearrangement, FISH, Tissue

	(IMT), 2p23 (ALK) Rearrangement, FISH, Tissue
□ FUSF	Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11.2 (<i>FUS</i> or <i>TLS</i>) Rearrangement, FISH, Tissue
□ MDM2F	MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/ Atypical Lipomatous Tumor, FISH, Tissue
☐ MYODT	MYOD1 Mutation Analysis, Next-Generation Sequencing, Tumor
□ DDITF	Myxoid/Round Cell Liposarcoma, 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue
□ NR4A3	NR4A3 (9q22.33) Rearrangement, FISH, Tissue
□ PDGF	PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue
□ SS18F	Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue
☐ TGOGF	TGFBR3 (1p22), OGA (10q24) Rearrangement, FISH, Tissue
□ USPF	USP6 (17p13), Aneurysmal Bone Cyst and Nodular Fasciitis, FISH, Tissue

Inflammatory Myofibroblastic Tumors

☐ IMTF

Breast		
☐ MASF	Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue	
☐ BRCAT	BRCA1/2 Mutation Analysis, Next-Generation Sequencing, Tumor	
☐ PIK3B	Cell-Free DNA PIK3CA Test, Blood	
☐ ESR1T	ESR1 Mutations Analysis, Next-Generation Sequencing, Tumor	
☐ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue	
☐ H2BR	HER2 Amplification Associated with Breast Cancer, FISH, Tissue	
☐ ESR1T	ESR1 Mutations Analysis, Next-Generation Sequencing, Tumor	
☐ ETV6F	ETV6 (12p13.2) Rearrangement, FISH, Tissue	
☐ PIK3T	PIK3CA Mutation Analysis, Tumor	
	tochemical assays interpreted image analysis	
□ ERPR	Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual	
☐ KI67B	Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated	
☐ HERBA	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex	

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.			
Patient Name (Last, First Middle)	Client Order No.			
Birth Date (mm-dd-yyyy)				

Gastrointestinal					
□ BRAFD	BRAF V600E/V600K Somatic Mutation Analysis, Tumor				
□ EGFRS	EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor				
☐ PRKAF	Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue				
☐ FGFR2	FGFR2 (10q26.1) Rearrangement, FISH, Tissue				
☐ H2GE	HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue				
□ Н2МТ	HER2 Amplification, Miscellaneous Tumor, FISH, Tissue				
☐ KINET	Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated				
☐ METF	MET (7q31), FISH, Tissue				
□ мынм	MLH1 Hypermethylation Analysis, Tumor				
☐ MLHPE	<i>MLH1</i> Hypermethylation Analysis, Blood				
□ BRMLH	MLH1 Hypermethylation and BRAF Mutation Analysis, Tumor				
□ інс	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor				
☐ TMSI	Microsatellite Instability, Tumor				
Genitouri	nary				
☐ TFE3F	Alveolar Soft Part Sarcoma (ASPS)/ Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue				
☐ GCTF	Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue				
☐ H2UR	HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue				
□ мскся	MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor				
☐ FUROC	UroVysion for Detection of Bladder Cancer, Urine				
□ мсвря	MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor				
□ MCFRC	MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor				
□ NUT1F	NUTM1 (15q14) Rearrangement, FISH, Tissue				
☐ TFEBF	Renal Cell Carcinoma, 6p21.1 (TFEB) Rearrangement, FISH, Tissue				
□ SDHMF	SDH Genes Mutation Analysis, Next-Generation Sequencing, Tumor				
☐ TFH	FH Mutation Analysis, Next-Generation Sequencing, Tumor				

Gynecology		☐ GCTF	Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue		
□ ESTUF	Endometrial/Uterine Carcinoma ☐ ESTUF Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3		Histone Genes Mutation Analysis, Next-Generation Sequencing, Tumor		
☐ MCGYN	(YWHAE) Rearrangement, FISH, Tissue MayoComplete Gynecological Cancer	□ IDHT	IDH1/IDH2 Mutations Analysis, Next-Generation Sequencing, Tumor		
☐ MCECP	Panel, Next-Generation Sequencing, Tumor MayoComplete Endometrial Carcinoma	□ IDTRT	IDH1, IDH2, and TERT Mutation Analysis, Next-Generation Sequencing, Tumor		
	Panel, Next-Generation Sequencing, Tumor	☐ MGMT	, , , , , , , , , , , , , , , , , , , ,		
☐ ML1HM	MLH1 Hypermethylation Analysis, Tumor POLE Mutation Analysis, Next-Generation	□ NONCF	 Neuro-Oncology Expanded Panel with Rearrangement, Tumor 		
	Sequencing, Tumor	☐ TERTD	TERT Promoter Mutation Analysis, Droplet		
Ovarian Car	cinoma		Digital PCR, Tumor		
☐ XL2T	FOXL2 Mutations Analysis, Next-Generation Sequencing, Tumor	☐ TP53	TP53 Mutation Analysis, Next-Generation Sequencing, Tumor		
□ мсоср	MayoComplete Ovarian, Fallopian Tube,	Pulmonar	y		
	and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor	☐ ALKT	ALK Mutation Analysis, Next-Generation Sequencing, Tumor		
Lower Anal-	Genital Tract Carcinoma Human Papillomavirus (HPV)	☐ BRAFD	BRAF V600E/V600K Somatic Mutation Analysis, Tumor		
☐ HPVE6	High/Low Risk, In Situ Hybridization Human Papillomavirus (HPV)	□ EGFRS	EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor		
☐ HPVLR	High-Risk E6/E7, RNA In Situ Hybridization Human Papillomavirus (HPV), Low-Risk,	☐ EGFRW	EGFR Targeted Mutation Analysis with ALK Reflex, Tumor		
	In Situ Hybridization	☐ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue		
Head and N	eck	☐ KRASP	KRAS Somatic Mutation Analysis, Tumor		
☐ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue Human Papillomavirus (HPV)	□ LCAF	Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue		
☐ HPVE6	High/Low Risk, In Situ Hybridization Human Papillomavirus (HPV) High-Risk	☐ RETF	Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue		
☐ HPVLR	E6/E7, RNA In Situ Hybridization Human Papillomavirus (HPV), Low-Risk,	□ ROS1F	Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue		
	In Situ Hybridization	☐ MESOF	Mesothelioma, CDKN2A Fish, Tissue		
☐ MAMLF	MAML2 (11q21) Rearrangement, Mucoepidermoid Carcinoma (MEC),	☐ METF	MET (7q31), FISH, Tissue		
	FISH, Tissue	LIEDEDIT	A DV ONOGLOGY TECTING		
□ SGTF	MYB (6q23) Rearrangement, FISH, Tissue		ARY ONCOLOGY TESTING		
Melanoma	0 5 DNA DDA 5 / (200 DL	□ BAP1Z	BAP1-Tumor Predisposition Syndrome, BAP1 Full Gene Analysis		
☐ BRAFB ☐ BRAFD	Cell-Free DNA BRAF V600, Blood BRAF V600E/V600K Somatic Mutation	□ BHDZ	Birt-Hogg-Dube Syndrome, <i>FLCN</i> , Full Gene Analysis		
	Analysis, Tumor	□ нвосz	BRCA1/BRCA2 Genes, Full Gene Analysis		
□ BRFKT	BRAF/KIT Mutation Analysis, Next-Generation Sequencing, Tumor	☐ BRGYP	Hereditary Breast/Gynecologic Cancer Panel		
Neuro-Onc		☐ COMCF	P Hereditary Common Cancer Panel		
☐ GLIOF	1p/19q Deletion in Gliomas, FISH, Tissue	□ CDHZ	Hereditary Diffuse Gastric Cancer Syndrome, <i>CDH1</i> , Full Gene Analysis		
☐ ALKT	ALK Mutation Analysis, Next-Generation Sequencing, Tumor	☐ ENDCP	Hereditary Endocrine Cancer Panel		
□ BRAFD	BRAF V600E/V600K Somatic Mutation	□ XCP	Hereditary Expanded Cancer Panel		
	Analysis, Tumor	☐ CRCGP	•		
□ СМАРТ	Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded	□ LRCCZ	Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome, <i>FH</i> , Full Gene Analysis		
		· -			

Hereditary Pancreatic Cancer Panel

☐ PANCP

Patient i	Information (required)						
Patient ID (Medical Record No.)				Client Account No.			
Patient Name (Last, First Middle)				Client Order No.			
Birth Date	(mm-dd-yyyy)						
☐ HPGLP	Hereditary Paraganglioma/ Pheochromocytoma Panel	Pituitary Tu				☐ GAST	Gastrin, Serum
□ PRS8P	Hereditary Prostate Cancer Panel	□ ACTH		otropic Hormone, Plasma	[□ GLP	Glucagon, Plasma
☐ RENCP	Hereditary Renal Cancer Panel	☐ APGH	Alpha-Subun Serum	it Pituitary Tumor Marker,		☐ HCCGS	Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum
☐ THYRP	Hereditary Thyroid Cancer Panel	☐ FSH	Follicle-Stimu	ulating Hormone (FSH), Serum	[□ HIAA	5-Hydroxyindoleacetic Acid, 24 Hour, Urine
☐ WILMP	Hereditary Wilms Tumor Panel	□ HGH	Growth Horn	none, Serum	[□ NSE	Neuron-Specific Enolase, Serum
☐ LYNCP	Lynch Syndrome Panel	☐ LH	Luteinizing H	ormone (LH), Serum	[□ HPP	Pancreatic Polypeptide, Plasma
☐ RETZZ	Multiple Endocrine Neoplasia Type 2	☐ MCRPL	Macroprolact	tin, Serum	[SERU	Serotonin, 24 Hour, Urine
	Syndrome, RET, Full Gene Analysis	☐ NSE	Neuron-Spec	ific Enolase, Serum	[□ SERWB	Serotonin, Blood
☐ NF1Z	Neurofibromatosis Type 1, <i>NF1</i> , Full Gene Analysis	☐ PLPMA	Prolactin, Pitu	uitary Macroadenoma, Serum	[□ VIP	Vasoactive Intestinal Polypeptide, Plasma
☐ PTNZ	PTEN Hamartoma Tumor Syndrome,	☐ PRL	Prolactin, Ser	rum	-	Genitourin	ary
	PTEN Full Gene Analysis	Biogenic An			[☐ AFPSF	Alpha-Fetoprotein (AFP), Spinal Fluid
□ STK1Z	Peutz-Jeghers Syndrome, <i>STK11</i> , Full Gene Analysis	☐ CATU	24 Hour, Urin			□ AFP	Alpha-Fetoprotein (AFP) Tumor Marker, Serum
☐ BRTP	Rapid Hereditary Breast Cancer Treatment Decision Panel	☐ CATP	☐ CATP Catecholamine Fractionation, Free, Plasma ☐ HVA Homovanillic Acid, 24 Hour, Urine			□ BHCG	Beta-Human Chorionic Gonadotropin, Quantitative, Serum
□ UGTFZ	UDP-Glucuronosyltransferase 1A1 (UGT1A1), Full Gene Sequencing	□ HVAR	, ,		[□ BHSF	Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid
□ U1A1Q	UDP-Glucuronosyltransferase 1A1 TA	☐ HIAA ☐ METAF			[□ CEASF	Carcinoembryonic Antigen (CEA), Spinal Fluid
Repeat Genotype, UGT1A1 VHLZZ Von Hippel Lindau Syndrome, VHL, Full Gene Analysis		☐ PMET	MET Metanephrines, Fractionated, Free, Plasma			□ PSA	Prostate-Specific Antigen (PSA) Diagnostic
		☐ METRN	Metanephrine	hrines, Fractionated, Random, Urine			Serum
DRIMARY RODY ELLID TECTS		☐ SERU	Serotonin, 24	Hour, Urine	[□ SPSA	Prostate-Specific Antigen (PSA) Screen,
PRIMARY BODY FLUID TESTS TESTS FOR DISEASE MONITORING		☐ SERWB	Serotonin, Blo	pod	Ι,	¬	Serum
OR AIDING IN THE DIAGNOSIS		□ VH	,	elic Acid and Homovanillic		☐ PHI11	Prostate Health Index Reflex, Serum
Bone and Soft Tissue		□ VMA	Acid, Randon	delic Acid, 24 Hour, Urine		□ PSAFT	Prostate-Specific Antigen (PSA), Total and Free, Serum
☐ IFG23	Intact Fibroblast Growth Factor 23, Serum		•			Gynecology	·
Breast		□ VMAR	☐ VMAR Vanillylmandelic Acid, Rando Gastrointestinal		☐ BHCG Beta-Human Chorionic Gonadotropin,		
☐ C2729	2729 Breast Carcinoma-Associated Antigen, Serum		Alpha-Fetopr	rotein (AFP) L3% and Total,		☐ CA25	Quantitative, Serum Cancer Antigen 125 (CA 125), Serum
☐ CA153	Cancer Antigen 15-3 (CA 15-3), Serum		Hepatocellula Serum	ılar Carcinoma Tumor Marker,		□ HE4	Human Epididymis Protein 4, Serum
Endocrine		☐ AFPPT		otein (AFP), Peritoneal Fluid		□ INHA	Inhibin A, Tumor Marker, Serum
Thyroid Car		☐ AFP		otein (AFP) Tumor Marker,		□ INHAB	Inhibin A and B, Tumor Marker, Serum
☐ CATLN	Calcitonin, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash, Lymph Node		Serum		[□ INHB	Inhibin B, Serum
☐ CATN	Calcitonin, Serum	☐ AMLPC	Amylase, Pan	creatic Cyst Fluid	[□ ROMA	ROMA Score (Ovarian Malignancy Risk
☐ CEA	Carcinoembryonic Antigen (CEA), Serum	☐ 199PC	Carbohydrate Pancreatic Cy	e Antigen 19-9 (CA 19-9),	L		Algorithm), Serum
☐ TGMS	Thyroglobulin Mass Spectrometry, Serum	☐ 199PT	•	e Antigen 19-9 (CA 19-9),		Pulmonary	
☐ TFNAB	Thyroglobulin, Tumor Marker, Fine-Needle Aspiration Biopsy Needle Wash	□ CA19	Peritoneal Flu			□ PF199	Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid
☐ HTGR	Thyroglobulin, Tumor Marker Reflex, Serum	☐ CEAPC	•		ال	☐ PFCEA	Carcinoembryonic Antigen (CEA), Pleural Fluid
CLAFC CAICIII		Pancreatic Cy	ryonic Antigen (CEA), Cyst Fluid		□ NSE	Neuron-Specific Enolase (NSE), Serum	
		☐ CEAPT	CEAPT Carcinoembryonic Antigen (CEA),		_		
☐ CGAK Chromogranin A, Serum			Peritoneal Flu				AL TESTS TEST ID AND NAME)
☐ GAST	Gastrin, Serum	□ CEA		yonic Antigen (CEA), Serum			
☐ GLP	Glucagon, Plasma	☐ CGAK	Chromograni				
☐ NSE	Neuron-Specific Enolase, Serum		DCP Des-Gamma-Carboxy Prothrombin, Serum				
☐ HPP	Pancreatic Polypeptide, Plasma	☐ FOBT		Blood, Colorectal Cancer tative, Immunochemical, Feces			
☐ VIP	Vasoactive Intestinal Polypeptide, Plasma		Jorden, Quali	anve, minumochemical, reces			